Predictors of diabetes-related distress before and after FreeStyle Libre-1 use: Lessons from the Association of British Clinical Diabetologists nationwide study (2021)
Journal Article
Deshmukh, H., Wilmot, E. G., Gregory, R., Barnes, D., Narendran, P., Saunders, S., …Sathyapalan, T. (2021). Predictors of diabetes-related distress before and after FreeStyle Libre-1 use: Lessons from the Association of British Clinical Diabetologists nationwide study. Diabetes, Obesity and Metabolism, 23(10), 2261-2268. https://doi.org/10.1111/dom.14467

Aim: To identify the baseline demographic and clinical characteristics associated with diabetes-related distress (DRD) and factors associated with improvement in DRD after initiating use of the FreeStyle Libre (FSL) in people living with type 1 diabe... Read More about Predictors of diabetes-related distress before and after FreeStyle Libre-1 use: Lessons from the Association of British Clinical Diabetologists nationwide study.

The Effect of Free Androgen Index on the Quality of Life of Women With Polycystic Ovary Syndrome: A Cross-Sectional Study (2021)
Journal Article
Abdalla, M. A., Deshmukh, H., Mohammed, I., Atkin, S., Reid, M., & Sathyapalan, T. (2021). The Effect of Free Androgen Index on the Quality of Life of Women With Polycystic Ovary Syndrome: A Cross-Sectional Study. Frontiers in Physiology, 12, Article 652559. https://doi.org/10.3389/fphys.2021.652559

Purpose: Free androgen index (FAI) and anti-Mullerian hormone (AMH) are independently associated with polycystic ovary syndrome (PCOS). This study aimed to describe the relationship between these two markers and health-related quality of life (HR-QoL... Read More about The Effect of Free Androgen Index on the Quality of Life of Women With Polycystic Ovary Syndrome: A Cross-Sectional Study.

The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence (2021)
Journal Article
Abdalla, M. A., Deshmukh, H., Atkin, S., & Sathyapalan, T. (2021). The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence. Therapeutic Advances in Endocrinology and Metabolism, 12, https://doi.org/10.1177/2042018821989238

© The Author(s), 2021. Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects women of reproductive age. Metabolic consequences associated with PCOS include, but are not limited to, insulin resistance (IR), type 2... Read More about The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.

Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice (2021)
Journal Article
Shah, N., Abdalla, M. A., Deshmukh, H., & Sathyapalan, T. (2021). Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. Therapeutic Advances in Endocrinology and Metabolism, 12, https://doi.org/10.1177/20420188211042145

Diabetes mellitus (DM) is a chronic, progressive, and multifaceted illness resulting in significant physical and psychological detriment to patients. As of 2019, 463 million people are estimated to be living with DM worldwide, out of which 90% have t... Read More about Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice.

Hyperthyroidism, and bone mineral density : dissecting the causal association with Mendelian randomization analysis (2020)
Journal Article
Deshmukh, H., Papageorgiou, M., Aye, M., England, J., Abdalla, M., & Sathyapalan, T. (in press). Hyperthyroidism, and bone mineral density : dissecting the causal association with Mendelian randomization analysis. Clinical Endocrinology, https://doi.org/10.1111/cen.14330

Introduction Untreated hyperthyroidism is associated with accelerated bone turnover, low bone mineral density (BMD) and increased susceptibility to fragility fractures. Although treatment appears to improve or even reverse some of these adverse skel... Read More about Hyperthyroidism, and bone mineral density : dissecting the causal association with Mendelian randomization analysis.

miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): A review (2020)
Journal Article
Abdalla, M., Deshmukh, H., Atkin, S. L., & Sathyapalan, T. (2020). miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): A review. Life Sciences, 259, https://doi.org/10.1016/j.lfs.2020.118174

© 2020 Elsevier Inc. Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in females of the reproductive age. PCOS is commonly manifested as ovulatory dysfunction, clinical and biochemical excess androgen level, and polycystic ov... Read More about miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): A review.

Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the association of british clinical diabetologists (Abcd) nationwide audit (2020)
Journal Article
Deshmukh, H., Wilmot, E. G., Gregory, R., Barnes, D., Narendran, P., Saunders, S., …Sathyapalan, T. (2020). Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the association of british clinical diabetologists (Abcd) nationwide audit. Diabetes Care, 43(9), 2153-2160. https://doi.org/10.2337/dc20-0738

OBJECTIVE The FreeStyle Libre (FSL) flash glucose-monitoring device was made available on the U.K. National Health Service (NHS) drug tariff in 2017. This study aims to explore the U.K. real-world experience of FSL and the impact on glycemic control,... Read More about Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the association of british clinical diabetologists (Abcd) nationwide audit.

Association of endocrine active environmental compounds with body mass index and weight loss following bariatric surgery (2020)
Journal Article
Deshmukh, H., Aylward, L. L., Rose, M., Fernandes, A., Sedman, P., Thatcher, N. J., …Sathyapalan, T. (2020). Association of endocrine active environmental compounds with body mass index and weight loss following bariatric surgery. Clinical Endocrinology, 93(3), 280-287. https://doi.org/10.1111/cen.14257

Introduction The objective of this study was to study associations of a wide range of halogenated biphenyls, dibenzo‐p‐dioxins, dibenzofurans, and diphenylethers with body mass index (BMI) and evaluate changes in their concentration following bariat... Read More about Association of endocrine active environmental compounds with body mass index and weight loss following bariatric surgery.

A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome (2020)
Journal Article
Abdalla, M. A., Deshmukh, H., Atkin, S., & Sathyapalan, T. (2020). A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Therapeutic Advances in Endocrinology and Metabolism, 11, https://doi.org/10.1177/2042018820938305

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. Metabolic sequelae associated with PCOS range from insulin resistance to type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Insulin resistanc... Read More about A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome.

Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study (2019)
Journal Article
Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., …Sathyapalan, T. (2019). Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clinical Endocrinology, 90(6), 805-813. https://doi.org/10.1111/cen.13968

Background: Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type 2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascu... Read More about Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study.